scispace - formally typeset
R

Ronald J. Voll

Researcher at Emory University

Publications -  70
Citations -  1190

Ronald J. Voll is an academic researcher from Emory University. The author has contributed to research in topics: Dopamine transporter & Serotonin transporter. The author has an hindex of 19, co-authored 68 publications receiving 1115 citations. Previous affiliations of Ronald J. Voll include Yerkes National Primate Research Center.

Papers
More filters
Journal ArticleDOI

Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2'-amino-4'-substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands.

TL;DR: Substitution at the 4'-position of the dimethylated and monomethylated benzylamines differently influenced SERT binding, and alkyl, alkenyl, or hydroxymethyl functions at the 3'-position afford compounds with high SERT affinity, and omega-hydroxy and fluoro-substituted ethyl and propyl groups at the4'-position decrease the SERT preference.
Journal ArticleDOI

The relation of developmental changes in brain serotonin transporter (5HTT) and 5HT1A receptor binding to emotional behavior in female rhesus monkeys: effects of social status and 5HTT genotype.

TL;DR: The findings indicate that adolescence in female rhesus monkeys is a period of central 5HT reorganization, partly influenced by exposure to the social stress of subordination, that likely functions to integrate adrenal and gonadal systems and shape the behavioral response to emotionally challenging social situations.
Journal ArticleDOI

Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.

TL;DR: Compound L-368,899 was successfully alkylated with [(11)C]iodomethane to generate the oxytocin receptor selective (2R)-2-amino-N-((2S)-7,7-dimethyl-1-(((4-(o-tolyl)piperazin- 1-yl)sulfonyl)methyl) methyl)bicyclo) with very high radiochemical purity and high specific activity.
Journal ArticleDOI

Synthesis and in vivo evaluation of halogenated N,N-dimethyl-2-(2'-amino-4'-hydroxymethylphenylthio)benzylamine derivatives as PET serotonin transporter ligands.

TL;DR: In vivo bindings of N, N-dimethyl-2-(2'-amino-4'-hydroxymethyl-phenylthio)-5-bromobenzylamine, substituted on ring A, were shown to be specific to the SERT as displacement with citalopram (a potent SERT ligand) reduced radioactivity in SERT-rich regions to the cerebellum level.